These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34719075)

  • 1. Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma.
    Liu HF; Xie YK; Zhong BY; Zhang JH; Song CX; Liu YW; Yang Y; Xie BH
    Cell Biol Int; 2022 Feb; 46(2):213-221. PubMed ID: 34719075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.
    Liu QQ; Liu YW; Xie YK; Zhang JH; Song CX; Wang JZ; Xie BH
    Cell Biol Int; 2021 Sep; 45(9):1906-1916. PubMed ID: 33969575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
    Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
    Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway.
    Yang Q; Xie B; Tang H; Meng W; Jia C; Zhang X; Zhang Y; Zhang J; Li H; Fu B
    J Exp Clin Cancer Res; 2019 Jun; 38(1):263. PubMed ID: 31208444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway.
    Shen ZT; Chen Y; Huang GC; Zhu XX; Wang R; Chen LB
    BMC Cancer; 2019 Nov; 19(1):1075. PubMed ID: 31703572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma.
    Li Y; Li J; Chen H; Wang J; Jiang L; Tan X
    J Biochem Mol Toxicol; 2022 Sep; 36(9):e23119. PubMed ID: 35678308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma.
    Li H; Hu J; Qiu L; Wu Y; Zhong B; Ye R; Xie B
    Anticancer Drugs; 2024 Jan; 35(1):55-62. PubMed ID: 37823256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
    Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
    Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis.
    Guo K; Kang NX; Li Y; Sun L; Gan L; Cui FJ; Gao MD; Liu KY
    BMC Cancer; 2009 Mar; 9():100. PubMed ID: 19331697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.
    Chowdhury S; Chen Y; Yao TW; Ajami K; Wang XM; Popov Y; Schuppan D; Bertolino P; McCaughan GW; Yu DM; Gorrell MD
    World J Gastroenterol; 2013 May; 19(19):2883-93. PubMed ID: 23704821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
    Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
    Sun T; Mao W; Peng H; Wang Q; Jiao L
    Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
    Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.